infliximab biosimilar / BioXpress Therap - LARVOL DELTA

Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study. (PubMed) - "SR was uncommon in patients with RA treated with anti-TNF in clinical practice. However, patients remained in SR for a substantial period of time. Concomitant MTX treatment predicts remission. ETN and ADA were more likely in reaching SR."

Journal • Biosimilar • Immunology • Inflammation • Rheumatoid Arthritis

Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. (PubMed) - "The risk of any AE among RA patients treated with bDMARDs was significantly higher compared to those treated with sDMARDs."

Journal • Biosimilar • Immunology • Inflammation • Rheumatoid Arthritis

Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. (PubMed) - "Anti-tumour necrosis factor therapy is more effective than placebo to induce and maintain clinical remission and mucosal healing. Both infliximab and adalimumab are associated with less hospitalisations. Infliximab reduces the need for colectomy. Anti-tumour necrosis factor therapy does not increase the risk of adverse events."

Journal • Biosimilar • Immunology • Inflammation • Inflammatory Bowel Disease

Systemic therapies for psoriasis: an evidence-based update. (PubMed) - "Current studies continue to support the use of biologic agents in the treatment of moderate to severe psoriasis, with better efficacy and safety profiles than traditional systemic agents. Newer anti-IL-17 agents and several new oral agents are in development and have shown promise in clinical trials."

Journal • Biosimilar • Immunology • Inflammation • Psoriasis

4 questions about the expected increase in biosimilars for IBD (Consultant360) - "Adam Cheifetz, MD...spoke with Gastroenterology Consultant about biosimilars following his presentation on the topic at the Advances in Inflammatory Bowel Diseases Regional Meeting in Boston, Massachusetts...Adam Cheifetz: I think other companies are interested in bringing more biosimilars to market....If they are not going to do proactive TDM with infliximab (and likely adalimumab), physicians should be using a combination immunomodulator (azathioprine or methotrexate) to increase drug concentrations and decrease immunogenicity, similar to the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) trial."

Media quote